Short description
Entero Therapeutics is a biopharmaceutical company specializing in the development of therapies for gastrointestinal diseases.
Description
Entero Therapeutics is a late clinical-stage biopharmaceutical company that develops targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs target key unmet needs in gastrointestinal health. These include latiglutenase, an advanced oral treatment for celiac disease; capeserod, a selective drug for conditions like gastroparesis; and adrulipase, an enzyme to help cystic fibrosis and chronic pancreatitis patients digest fats and nutrients.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Boca Raton, Florida, United States, North America
Founded on
January 1, 2014
Exited on
May 17
Went public on
May 17
Stock symbol
ENTO
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Founders
Daniel Dupret